The burden of childhood cancers in the South Asian Association for Regional Cooperation (SAARC) region: A GLOBOCAN 2022 analysis.

T Tara Pattilachan Menon (Virginia Tech Carilion School of Medicine, Roanoke, VA) J Jazlyn Selvasingh T Taral Kumar Jella (Virginia Tech Carilion School of Medicine, Roanoke, VA) C C.S. Pramesh (Tata Memorial Hospital, Mumbai, India) S Sanjeeva Gunasekera (National Cancer Institute, Sri Lanka, Maharagama, Sri Lanka) V Venkatraman Radhakrishnan M Maya Prasad (Division of Pediatric Oncology, Tata Memorial Centre, Mumbai, India) S Swati Goel (Department of Internal Medicine, University of California San Francisco School of Medicine, San Francisco, CA) S Shakeel Modak (Memorial Sloan Kettering Cancer Center, New York, NY) S Suzanne L. Wolden (Memorial Sloan Kettering Cancer Center, New York, NY) C Christopher Jackson (Memorial Sloan Kettering Cancer Center, New York, NY) B Bishal Gyawali E Edward Christopher Dee

Abstract

10022 Background: Countries of the South Asian Association for Regional Cooperation (SAARC) are home to approximately 600 million children aged 0–14 years, representing a quarter of the global child population. We report incidence and mortality for childhood cancers among South Asia's eight nations to inform priority setting for research, programming for health services, and policy for childhood cancers. Methods: Incidence and mortality of new childhood cancer diagnoses for all cancers combined and for selected leading diagnostic groups were retrieved from the GLOBOCAN 2022 database of Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka. Age-standardized incidence rates (ASR) and mortality-to-incidence ratios (MIR) were calculated, together with statistical examination of cross-country variation in diagnostic structure and survival trends. Results: In SAARC nations, 37,716 new childhood cancer diagnoses and 17,700 deaths were estimated in 2022. India contributed 68.7% of subregional cases (25,939), and Pakistan contributed 20.8% (7,841). Age-standardized rates differed and were greatest in Sri Lanka (10.4/100,000) and Pakistan (10.1) and lowest in Bhutan (2.3) and Bangladesh (3.7). Boys represented 60% of cases overall, with significant cross-country variation in sex distribution (χ²=18.0, p=0.012). Leukemia was the most common cancer in all countries (35–50%), followed by central nervous system (CNS) tumors. MIR ranged from 0.30 (Sri Lanka) to 0.57 (Afghanistan), reflecting extreme survival differences, with CNS tumors demonstrating disproportionately high mortality relative to incidence. Conclusions: SAARC childhood cancer trends reflect both population size influences and health system capacity, with a preponderance of leukemia but alarming survival gaps, particularly for CNS cancers. These findings highlight actionable priorities, including strengthening population-based childhood cancer registries, centralizing care pathways for CNS tumors, expanding standardized leukemia treatment protocols with abandonment-prevention strategies, and improving equitable access to specialty care through subregional collaboration.

Article Details

Volume / Issue Vol. 44, Issue 16_suppl
Published June 01, 2026
Pages 10022-10022
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (13)

T

Tara Pattilachan Menon

Virginia Tech Carilion School of Medicine, Roanoke, VA

J

Jazlyn Selvasingh

T

Taral Kumar Jella

Virginia Tech Carilion School of Medicine, Roanoke, VA

C

C.S. Pramesh

Tata Memorial Hospital, Mumbai, India

S

Sanjeeva Gunasekera

National Cancer Institute, Sri Lanka, Maharagama, Sri Lanka

V

Venkatraman Radhakrishnan

M

Maya Prasad

Division of Pediatric Oncology, Tata Memorial Centre, Mumbai, India

S

Swati Goel

Department of Internal Medicine, University of California San Francisco School of Medicine, San Francisco, CA

S

Shakeel Modak

Memorial Sloan Kettering Cancer Center, New York, NY

S

Suzanne L. Wolden

Memorial Sloan Kettering Cancer Center, New York, NY

C

Christopher Jackson

Memorial Sloan Kettering Cancer Center, New York, NY

B

Bishal Gyawali

E

Edward Christopher Dee